New Delhi: Global pharmaceutical major Eli Lilly and Company has announced plans to invest more than $1 billion in India over the next few years to expand its manufacturing and supply operations through collaborations with local drugmakers. The move is part of the US-based firm’s global strategy to enhance production capacity and leverage India’s robust pharmaceutical manufacturing ecosystem.
According to the company, the upcoming investments will support the availability of its key drugs for obesity, diabetes, Alzheimer’s, cancer and autoimmune conditions. Eli Lilly said it is actively working with Indian contract manufacturers to produce complex drugs, vials and injectables, aiming to enhance efficiency and scale within its global supply chain.
Patrik Jonsson, President of Lilly International, reportedly said the investment underscores India’s role as a “hub for capability building” within the company’s global network. While the pharmaceutical giant currently does not have its own manufacturing facility in India, it has been strengthening its local presence through strategic partnerships. Earlier this year, Eli Lilly launched its blockbuster weight-loss and diabetes treatment, Mounjaro, in the Indian market.
The fresh investment is expected to deepen Eli Lilly’s integration with India’s rapidly growing pharmaceutical sector, which serves as a key global production base for many multinational drugmakers. The company, however, did not disclose details about specific partnerships or project timelines.
Also Read –
CapitaLand Investment Limited to Invest Over Rs 19,200 Cr in Maharashtra by 2030
